Report Code: A13412 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Transarterial chemoembolization is a procedure to treat liver cancer. It is a therapy for patients with intermediate-stage hepatocellular carcinoma (HCC), and working is based on blocking the blood supply to the tumor. Chemotherapy is given right into the tumor once the supply is blocked. Conventional transarterial chemoembolization is popular as a standard treatment for HCC. Transarterial chemoembolization also utilizes microspheres as drug carriers, which aids to decrease the concentration of chemotherapeutics in the systemic circulation of patients.
COVID-19 Impact analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the transarterial chemoembolization market.
Top Impacting Factors
Transarterial Chemoembolization Market Trends
New product launches to flourish the market
AstraZeneca is currently conducting three phases 3 studies to evaluate durvalumab. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1. One of the current studies includes EMERALD-1 (transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab). The safety and clinical activity of durvalumab monotherapy were reported in June of 2017.
Key Benefits of the Report
Questions answered in the transarterial chemoembolization Report
Transarterial Chemoembolization Market Report Highlights
Aspects | Details |
---|---|
By Product Type |
|
By Procedure Type |
|
By Indication |
|
By End User |
|
By Region |
|
Key Market Players | Merck & Co., Inc., Boston Scientific Corporation, Bayer AG, Spectrum Pharmaceuticals, Inc., Novartis AG, Cook, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Nippon Kayaku Co. Ltd., Siemens Healthcare GmbH, Questex LLC., Bellicum Pharmaceuticals Inc., Pfizer Inc., CELGENE CORPORATION |
Loading Table Of Content...
Start reading.
This Report and over 71,223+ more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
15%
Discount
15%
Discount
Enterprise
License/PDF
20%
Discount
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers